COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #54 of 258
6/9 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Bhattacharya et al., medRxix, doi:10.1101/2020.06.09.20116806 (Preprint)
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers
Source   PDF   Share   Tweet
HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.

Bhattacharya et al., 6/9/2020, retrospective, India, South Asia, preprint, 7 authors.
risk of COVID-19 case, 80.7% lower, RR 0.19, p = 0.001, treatment 4 of 54 (7.4%), control 20 of 52 (38.5%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 258 studies    Meta analysis
Please send us corrections, updates, or comments.